EP3551750A4 - GENE THERAPY TO TREAT MUCOPOLYSACCHARIDOSIS TYPE I - Google Patents

GENE THERAPY TO TREAT MUCOPOLYSACCHARIDOSIS TYPE I Download PDF

Info

Publication number
EP3551750A4
EP3551750A4 EP17877511.0A EP17877511A EP3551750A4 EP 3551750 A4 EP3551750 A4 EP 3551750A4 EP 17877511 A EP17877511 A EP 17877511A EP 3551750 A4 EP3551750 A4 EP 3551750A4
Authority
EP
European Patent Office
Prior art keywords
mucopolysaccharidosis
type
gene therapy
therapy
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP17877511.0A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3551750A1 (en
Inventor
Kendrick A. GOSS
Geoffrey B. PARSONS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bluebird Bio Inc
Original Assignee
Bluebird Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bluebird Bio Inc filed Critical Bluebird Bio Inc
Publication of EP3551750A1 publication Critical patent/EP3551750A1/en
Publication of EP3551750A4 publication Critical patent/EP3551750A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01076—L-Iduronidase (3.2.1.76)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
EP17877511.0A 2016-12-06 2017-12-06 GENE THERAPY TO TREAT MUCOPOLYSACCHARIDOSIS TYPE I Withdrawn EP3551750A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662430795P 2016-12-06 2016-12-06
PCT/US2017/064913 WO2018106807A1 (en) 2016-12-06 2017-12-06 Gene therapy for mucopolysaccharidosis, type i

Publications (2)

Publication Number Publication Date
EP3551750A1 EP3551750A1 (en) 2019-10-16
EP3551750A4 true EP3551750A4 (en) 2020-07-22

Family

ID=62491308

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17877511.0A Withdrawn EP3551750A4 (en) 2016-12-06 2017-12-06 GENE THERAPY TO TREAT MUCOPOLYSACCHARIDOSIS TYPE I

Country Status (13)

Country Link
US (1) US20220339296A1 (ko)
EP (1) EP3551750A4 (ko)
JP (1) JP2019536484A (ko)
KR (1) KR20190089988A (ko)
CN (1) CN110214182A (ko)
AU (1) AU2017370662A1 (ko)
BR (1) BR112019011635A2 (ko)
CA (1) CA3046079A1 (ko)
IL (1) IL267057A (ko)
MA (1) MA47847A (ko)
MX (1) MX2019006552A (ko)
RU (1) RU2019120721A (ko)
WO (1) WO2018106807A1 (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
MX2021001292A (es) * 2018-07-30 2021-07-15 Centro De Investig Energeticas Medioambientales Y Tecnologicas O A M P Metodos para la modificacion genica de celulas hematopoyeticas.
CN115109790A (zh) * 2021-03-23 2022-09-27 北京据德医药科技有限公司 一种重组a-L-艾杜糖醛酸普酶及其制备方法
KR20240024807A (ko) * 2021-06-08 2024-02-26 터치라이트 아이피 리미티드 렌티바이러스 벡터
WO2024201066A1 (en) * 2023-03-31 2024-10-03 Dawn Therapeutics Limited Novel vector

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110294114A1 (en) * 2009-12-04 2011-12-01 Cincinnati Children's Hospital Medical Center Optimization of determinants for successful genetic correction of diseases, mediated by hematopoietic stem cells
EP3413896A1 (en) * 2016-02-12 2018-12-19 Bluebird Bio, Inc. Vcn enhancer compositions and methods of using the same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2872170B1 (fr) * 2004-06-25 2006-11-10 Centre Nat Rech Scient Cnrse Lentivirus non interactif et non replicatif, preparation et utilisations
JP6143231B2 (ja) * 2011-06-10 2017-06-07 ブルーバード バイオ， インコーポレイテッド 副腎脳白質ジストロフィおよび副腎脊髄神経障害のための遺伝子療法ベクター
WO2013175446A1 (en) * 2012-05-25 2013-11-28 Commissariat A L'energie Atomique Et Aux Energies Alternatives Vector for the selective silencing of a gene in astrocytes
EP3567112A1 (en) * 2013-06-13 2019-11-13 Translate Bio, Inc. Messenger rna based viral production

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110294114A1 (en) * 2009-12-04 2011-12-01 Cincinnati Children's Hospital Medical Center Optimization of determinants for successful genetic correction of diseases, mediated by hematopoietic stem cells
EP3413896A1 (en) * 2016-02-12 2018-12-19 Bluebird Bio, Inc. Vcn enhancer compositions and methods of using the same

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DI NATALE P ET AL: "In vitro gene therapy of mucopolysaccharidosis type I by lentiviral vectors", EUROPEAN JOURNAL OF BIOCHEMISTRY, WILEY-BLACKWELL PUBLISHING LTD, GB, vol. 269, no. 11, 1 June 2002 (2002-06-01), pages 2764 - 2771, XP002978473, ISSN: 0014-2956, DOI: 10.1046/J.1432-1033.2002.02951.X *
LI OU ET AL: "Elements of lentiviral vector design toward gene therapy for treating mucopolysaccharidosis I", MOLECULAR GENETICS AND METABOLISM REPORTS, vol. 8, 1 September 2016 (2016-09-01), pages 87 - 93, XP055702720, ISSN: 2214-4269, DOI: 10.1016/j.ymgmr.2015.11.004 *
See also references of WO2018106807A1 *

Also Published As

Publication number Publication date
CN110214182A (zh) 2019-09-06
RU2019120721A (ru) 2021-01-11
IL267057A (en) 2019-08-29
AU2017370662A1 (en) 2019-06-27
MX2019006552A (es) 2019-10-15
KR20190089988A (ko) 2019-07-31
JP2019536484A (ja) 2019-12-19
EP3551750A1 (en) 2019-10-16
BR112019011635A2 (pt) 2019-11-12
US20220339296A1 (en) 2022-10-27
WO2018106807A1 (en) 2018-06-14
MA47847A (fr) 2020-01-29
CA3046079A1 (en) 2018-06-14

Similar Documents

Publication Publication Date Title
EP3562494A4 (en) GENE THERAPY FOR TREATMENT OF PHENYLKETONURIA
EP3692158A4 (en) GENE THERAPIES FOR LYSOSOMIAL DISORDERS
EP3579858A4 (en) GENE THERAPY AGAINST HAPLOINSUFFICIENCY
IL260959A (en) Gene therapy for the treatment of mucoid polysaccharomyces type i
EP3236974A4 (en) Rna interference agents for gst-pi gene modulation
IL284577A (en) Garden healing
EP3289080A4 (en) Gene therapy for autosomal dominant diseases
EP3692075A4 (en) GENE THERAPIES FOR LYSOSOMAL DISEASES
EP3692151A4 (en) GENE THERAPIES FOR LYSOSOMAL DISORDERS
EP3092310A4 (en) Rna-guided gene drives
EP3189143A4 (en) Globin gene therapy for treating hemoglobinopathies
IL271780A (en) AAV9-mediated gene therapy for the treatment of type I mucositis
IL262211A (en) Gene therapy for the treatment of type ii mucositis
EP3717652A4 (en) GENE THERAPY FOR MUCOPOLY SACCHARIDOSIS IIIB
EP3160478A4 (en) Optimized factor ix gene
EP3717653A4 (en) GENE THERAPY FOR MUCOPOLYSACCHARIDOSIS TYPE IIIA
EP3551750A4 (en) GENE THERAPY TO TREAT MUCOPOLYSACCHARIDOSIS TYPE I
EP3359556A4 (en) MODULATION OF ACTIVITY OF GAMMA-C CYTOKINES
EP3290518A4 (en) Novel gene targeting method
EP3385386A4 (en) Carrimycin biosynthetic gene cluster
EP3442544A4 (en) IMPROVED GENE RELEASE PROCEDURES
GB201707212D0 (en) Gene therapy for ciliopathies
EP3295959A4 (en) Cmlck gene introduction
EP3271462A4 (en) System for stable gene expression
EP3279323A4 (en) Amadoriase having improved specific activity

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190704

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

A4 Supplementary search report drawn up and despatched

Effective date: 20200619

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 35/76 20150101ALI20200615BHEP

Ipc: C12N 7/00 20060101AFI20200615BHEP

Ipc: C12N 15/86 20060101ALI20200615BHEP

Ipc: A61K 38/43 20060101ALI20200615BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20220701